UroGen Pharma
UroGen is a company committed to elevating options for people living with urological cancers through breakthrough technology and transformative therapies.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
UroGen is a pharmaceutical company focused on urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen is committed to conducting business with high ethical standards and has adopted a Comprehensive Compliance Program.
History
UroGen is a company committed to elevating options for people living with urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen has a Comprehensive Compliance Program and is led by President and CEO Liz Barrett.
Products and positioning
Jelmyto
FDA-approved treatment leveraging RTGel technology
Zusduri
FDA-approved treatment leveraging RTGel technology
Recent events
UroGen lowers 2026 JELMYTO revenue guidance[6]
Reported:
UroGen updated its full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, down from its prior range of $97 million to $101 million.
UroGen reports third-quarter 2026 financial results[6]
Reported:
UroGen Pharma Ltd. announced its third-quarter 2026 financial results, reporting total revenue of $89.0 million and a net loss of $1.5 million.
FDA approves Jelmyto for low-grade upper tract urothelial cancer[7]
Reported:
The FDA approved mitomycin gel, marketed as Jelmyto by UroGen Pharma, for the treatment of low-grade upper tract urothelial cancer.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/urogen-pharma · Editorial policy · How profiles are compiled